Key result
PDGF-BB stimulates mesangial-cell hyperplasia with sustained MAP kinase activation, whereas angiotensin II causes hypertrophy with transient MAP kinase activation.
The differing potency and duration of MAP kinase activation by PDGF-BB and angiotensin II may explain their distinct effects on mesangial cell hyperplasia versus hypertrophy.
Differential MAP kinase signaling may drive mesangial phenotypes in kidney disease; hypothesis-generating for targeted human therapies.
Exposure of mesangial cells to platelet-derived growth factor (PDGF) BB caused a significant stimulation of cell proliferation and protein synthesis, as measured by [3H]thymidine incorporation and [3H]leucine incorporation respectively. In contrast, cells treated with angiotensin II had no significant increase in [3H]thymidine incorporation, but demonstrated a marked increase in [3H]leucine incorporation. Furthermore, angiotensin II significantly increased total protein content per cell. These data show that, whereas PDGF-BB is a mitogen and stimulates mesangial-cell hyperplasia, angiotensin II causes hypertrophy of the cells without hyperplasia. Treatment of mesangial cells with PDGF and angiotensin II rapidly and dose-dependently stimulated mitogen-activated protein (MAP) kinase activity, as shown by an assay for activity in vitro using myelin basic protein as a substrate, and by immunoprecipitation of 32P-labelled cells with specific antibodies against the 42 kDa and 44 kDa mitogen-activated protein kinases p42mapk and p44mapk, respectively. Whereas stimulation with PDGF-BB caused a potent and sustained (for more than 30 min) phosphorylation and activation of p42mapk and p44mapk, as well as of the upstream activators MAP kinase kinase and c-Raf, the effect of angiotensin II was less potent, reaching a peak at 5-10 min and thereafter declining rapidly. In summary, these results suggest that PDGF-BB and angiotensin II differ in their potency and duration of activation of the MAP kinase cascade, which may explain why PDGF-BB is a potent mitogen for mesangial cells, whereas angiotensin II only triggers mesangial-cell hypertrophy.
No takes yet. Share an insight, caveat, or question.
Huwiler et al. (1995) studied this question. Platelet-derived growth factor (PDGF) BB and angiotensin II was evaluated on MAP kinase activity, cell proliferation, and protein synthesis. PDGF-BB stimulates mesangial-cell hyperplasia with sustained MAP kinase activation, whereas angiotensin II causes hypertrophy with transient MAP kinase activation.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: